Suppression of megakaryocytopoiesis by neutrophil activating pep

Details Suppression of megakaryocytopoiesis by neutrophil activating pep Suppression of megakaryocytopoiesis by neutrophil activating pep

1993-12-27

1995-12-05

Warden, Jill

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, 530300, 530324, A61K 3800, C07K 500, C07K 700, A01N 3718

Patent

active

054729440

ABSTRACT:
Neutrophil activating peptide-2 or analog thereof is administered to a mammal to achieve therapeutic reduction of the number of circulating platelets. The peptide is useful in treating essential thrombocythemia and reactive thrombocytosis.

REFERENCES:
Baggiolini et al., Chem Abstract, vol. 114, No. 17, p. 606, Abst No. 114:162314e Apr. 29, 1991.
Walz et al., Chem. Abstr. vol. 117, p. 497 Abst. No. 117:24281c, 1992.
Holt et al., Chem Abst. vol. 116, Abst. No. 116:104136d, 1992.

Affiliated with

Also associated with

Rating

Suppression of megakaryocytopoiesis by neutrophil activating pep does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Suppression of megakaryocytopoiesis by neutrophil activating pep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of megakaryocytopoiesis by neutrophil activating pep will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1374189